Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60years of age in the Republic of Korea

Authors
Choi, Won SukNoh, Ji YunLee, JacobChoi, Jun YongLee, Jin-SooKim, Moo SooKim, Hee SooBang, JoonLavis, NathalieKim, Woo Joo
Issue Date
2018
Publisher
TAYLOR & FRANCIS INC
Keywords
quadrivalent influenza vaccine; inactivated influenza vaccine; adults; Republic of Korea
Citation
HUMAN VACCINES & IMMUNOTHERAPEUTICS, v.14, no.3, pp.587 - 592
Indexed
SCIE
SCOPUS
Journal Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume
14
Number
3
Start Page
587
End Page
592
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/80919
DOI
10.1080/21645515.2017.1381808
ISSN
2164-5515
Abstract
VaxigripTetra (R) (Sanofi Pasteur, Lyon, France) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) containing two B-lineage strains approved in the European Union and Taiwan in 2016 for individuals 3years of age. Here, we describe an observer-blind, randomized, controlled, multicenter trial study evaluating the immunogenicity and safety of the Northern Hemisphere 2015-2016 formulations of IIV4 and the licensed split-virion trivalent inactivated influenza vaccine (IIV3) in the Republic of Korea (ClinicalTrials.gov no. NCT02550197). The study included 300 Korean adults 18-60years of age randomized 2:1 to receive a single injection of IIV4 or IIV3. For each of the four vaccine strains in IIV4, 21days after vaccination, geometric mean post-/pre-vaccination ratios of hemagglutination inhibition titers were 3.97. Seroconversion/significant increases rates were 40% for all but the A/H1N1 strain, for which the rate was 39.7%. Results were similar for the three strains in IIV3. For the additional B-lineage strain not in IIV3 (Victoria), hemagglutination inhibition antibody titers were higher for IIV4 than for IIV3. Solicited reactions and adverse events were similar between IIV4 and IIV3, and no serious adverse events or new safety signals were detected. These results confirm the robust immunogenicity and acceptable safety of IIV4 in adults 18-60years of age and show that including a second B-lineage strain should provide broader protection against B-strain influenza without affecting vaccine safety or the immunogenicity of other three vaccine strains.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Noh, Ji Yun photo

Noh, Ji Yun
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE